P2Y12 regulates microglia activation and excitatory synaptic transmission in spinal lamina II neurons during neuropathic pain in rodents

Tingting Yu1, Xin Zhang1,2, Haosong Shi3, Jinge Tian1,4, Lingling Sun1, Xueming Hu5, Wenqiang Cui5 and Dongping Du1

Abstract
Peripheral nerve injury causes neuropathic pain and microglia activation. P2Y12 receptors on microglia are thought to be a key player in the surveillance of the local environment, but whether or how these receptors are engaged in the cross-talk between microglia and neurons of the dorsal horn remain ambiguous. Using a rodent model of nerve injury-induced pain, we investigated the roles of P2Y12 in microglia activation, excitatory synaptic transmission, and nociceptive allodynia. We found that spinal nerve ligation (SNL) significantly increased the level of P2Y12 receptors specifically in the microglia of the ipsilateral dorsal horn. Injections of P2Y12 antagonists (MRS2395 or clopidogrel) attenuated microglia activation and increased the paw withdrawal latency in response to thermal stimuli on the ipsilateral side without affecting the basal threshold on the contralateral side. These effects on pain behaviors were replicated in P2Y12 knockout mice. Patch-clamp recordings further revealed that partial sciatic nerve ligation (PSNL)-induced excessive miniature excitatory postsynaptic currents (mEPSCs) were significantly attenuated in P2Y12 knockout mice. Moreover, we found that SNL activates the GTP-RhoA/ROCK2 signaling pathway and elevates the level of phosphorylated p38 mitogen-activated protein kinase (MAPK), which was inhibited by the P2Y12 antagonist. The phosphorylation of p38 MAPK was inhibited by a ROCK inhibitor, but not vice versa, suggesting that p38 MAPK is downstream of ROCK activation. Our findings suggest that nerve injury engages the P2Y12 receptor-dependent GTP-RhoA/ROCK2 signaling pathway to upregulate excitatory synaptic transmission in the dorsal horn. This cross-talk ultimately participates in the manifestation of nociceptive allodynia, implicating P2Y12 receptor as a potential target for alleviating neuropathic pain.

Introduction
Nerve injury-induced neuropathic pain involves painful responses evoked by normally innocuous tactile stimuli, and it is one of the most challenging clinical problems1. However, the currently available therapeutics for this pathological pain are relatively limited.
P2X4 and P2X7, have important roles in chronic pain. Among them, P2Y12, a P2Y metabotropic G-protein-coupled purinergic receptors, has become a new focus. Research shows that P2Y12 is constitutively involved in cancer pain, synaptic plasticity in the mouse visual cortex and ATP-induced membrane ruffling and chemotaxis. P2Y12 is restrictively expressed on microglia in the central nervous system. Once microglia are activated, neurotransmitters and inflammatory cytokines are released, which regulate neuronal function, but whether P2Y12 is involved in the changes in neuronal function has never been reported before.

Neuropathic pain is thought to be initiated by a series of changes in the sensory processing system, such as the functional reorganization of sensory transmission or aberrant development of neural plasticity. Our focus is on the superficial dorsal horn, especially the substantia gelatinosa (SG) area, which is highly involved in modulating nociceptive transmission. In a previous study, whole-cell patch-clamp techniques were adapted to SG neurons in a spinal cord slice with an attached dorsal root to investigate synaptic responses to peripheral nerve stimulation. However, our method involved stimulating the SG neurons directly and then assessing the miniature excitatory postsynaptic current (mEPSC) changes. Furthermore, the shape of EPSCs is determined by many factors, such as the amount of presynaptically released glutamate, the properties of postsynaptic glutamate receptors and the time course of glutamate clearance from the synaptic cleft.

Antagonists of P2Y12 have been reported to attenuate inflammatory and neuropathic pain. In our study, we confirmed that P2Y12 is involved in the pathological activation of microglia, a process that is presumably involved in synapse remodeling and neural plasticity. We also confirmed the underlying molecular signaling pathway between P2Y12 and neuropathic pain, involving p38 mitogen-activated protein kinase (MAPK) and GTP-RhoA/Rho-associated coiled-coil-forming protein serine/threonine kinase 2 (ROCK2). Our data demonstrate that P2Y12 antagonists can potently inhibit the activation of microglia and the classic signaling pathway of microglia. Most important of all, P2Y12 knockout mice showed lower mEPSC increases after nerve injury than wild-type (WT) mice.

Results

Spinal nerve ligation increased the expression of P2Y12

The western blot analyses were used to determine the effect of spinal nerve ligation (SNL) surgery on P2Y12 expression in the spinal cord (Fig. 1a). Analysis of different time points revealed that the P2Y12 expression was increased from day 3 to 14 after SNL surgery compared to the expression in the sham group (Fig. 1a, b). Similarly, the fluorescence immunohistochemistry results showed that there was more P2Y12-immunoreactive cells per 400-μm length visual field per section on day 3 and 7 in the SNL group than in the sham group (Fig. 1c, d).
MRS2395 and clopidogrel inhibited the development of tactile allodynia and thermal hyperalgesia induced by SNL surgery

The experimental design and timeline for the experimental rats are shown in Fig. 2a. SNL surgery decreased the threshold of tactile allodynia (based on 50% paw withdrawal threshold) (Fig. 2b–g) and thermal hyperalgesia (based on paw withdrawal latency) (Fig. 2d–i). Regarding mechanical nociceptive testing in the ipsilateral paw (Fig. 2b–f), the mechanical nociceptive threshold decreased from day 1 to 10 after SNL surgery, while after MRS2395 treatment, the threshold was partially reversed.
at days 1, 3, 5, and 7 after surgery (Fig. 2b). Simulta-
neously, oral clopidogrel administration attenuated the
mechanical threshold at days 1, 3, and 5 after surgery in
the ipsilateral paw (Fig. 2f). Thus, daily administration of
MRS2395 or clopidogrel partially prevented the SNL-
induced mechanical allodynia.

Regarding thermal latency testing (Fig. 2d–h),
SNL surgery caused thermal hyperalgesia from day 1
to 10 in the ipsilateral paw compared with that in
the sham group and it was alleviated by daily adminis-
tration of MRS2395 (Fig. 2d) or clopidogrel (Fig. 2h)
from day 1 to 5 after surgery. At the same time,
the nociceptive behavior of the contralateral paw was
also verified, and there were no significant differences
in the mechanical withdrawal threshold (Fig. 2c–g) or
thermal paw latency (Fig. 2e–i) in the SNL-only group
compared with the MRS2395- or clopidogrel-treated
group.

P2Y12 was co-localized with ionized Ca\textsuperscript{2+}-binding adapter
molecule 1 (iba-1) in the spinal cord

As shown in Fig. 3, P2Y12 was strongly co-localized
with iba-1 (a microglia activation marker) in the spinal
cord 7 days after SNL surgery. Additionally, the higher-
magnification images excluded the co-localization of
P2Y12 with astrocytes, oligodendrocytes, or neurons
based on double immunostaining involving P2Y12 plus
glial fibrillary acidic protein (GFAP), oligo 2 or NeuN,
respectively.

P2Y12 antagonist changed the activation state
of microglia in SNL rats

To determine whether P2Y12 is involved in microglia
activation, we used western blotting to analyze the
expression of iba-1 in the ipsilateral spinal cord of rats in
different treatment groups (Sham, SNL, SNL + MRS2395,
SNL + clopidogrel) (Fig. 4a, b). MRS2395 or clopidogrel
Fig. 4 (See legend on next page.)
partially reversed the upregulation of iba-1 after SNL surgery (Fig. 4b), indicating that P2Y12 antagonists can inhibit the activation of microglia after nerve injury. Additionally, we used fluorescence immunohistochemistry to compare the fluorescence intensity of iba-1 in the ipsilateral or contralateral spinal dorsal horn in the different treatment groups. When SNL rats were intrathecally (i.t.) treated with MRS2397, the fluorescence intensity of iba-1 in the ipsilateral side was significantly decreased (Fig. 4c–e). Moreover, the morphology of microglia indicated a nonactivated state with small cell bodies and more ramified processes on the contralateral side in the SNL group and on both sides in the MRS2395 group (Fig. 4c, d). However, microglia were significantly activated on the ipsilateral side in the SNL group, with swollen cell bodies and retracted processes (Fig. 4c).

Furthermore, the relative fluorescence density of iba-1 and P2Y12 in the ipsilateral spinal dorsal horn from the SNL group was significantly decreased after MRS2395 treatment (Fig. 4e). It is noteworthy that microglia proliferation occurred after nerve injury (Fig. S1). Lastly, the proportional increase in P2Y12 intensity was higher than the proportional increase in the number of P2Y12-positive cells (Fig. 1d), which indicates a simultaneous increase in the intensity of the cells.

P2Y12 antagonist reduced the expression of p-p38 MAPK, and p38 MAPK inhibitor alleviated SNL-induced pain behavior

To determine the contributors to the increased P2Y12 expression in microglia, we assessed the possible downstream regulator: MAPK. We used immunofluorescence double staining to verify whether p-extracellular signal-regulated kinase (ERK), p-c-Jun N-terminal kinase (JNK), and/or p-p38 are activated in SNL rats and thus which MAPK signaling pathways are associated with microglia activation. As shown in Fig. 5a–c, p-p38 was highly expressed in the dorsal horn after SNL and exclusively colocalized with iba-1 (Fig. 5b), but this was not the case for p-ERK (Fig. 5a) or p-JNK (Fig. 5c). In addition, we found that the phosphorylation of p38 MAPK had the same time pattern as P2Y12 expression after SNL (Fig. 5d). Western blot analysis revealed that SNL increased the phosphorylation of p38 MAPK at days 3, 7, and 14 after surgery (Fig. 5d, e), and MRS2395 partially reversed the upregulation of p-p38 expression (Fig. 5f, g). Furthermore, as shown in Fig. 5h, i, an inhibitor of p38 MAPK, SB203580, partially suppressed pain behaviors in SNL rats. Mechanical allodynia was alleviated at days 1, 3, 5, and 7 after surgery (Fig. 5h). Thermal hyperalgesia was alleviated at days 1, 3, and 5 (Fig. 5i). SB203580 alone had no effect on the mechanical allodynia threshold or thermal hyperalgesia latency.

Inhibition of RhoA/ROCK suppresses SNL-induced pain reflex and p38 phosphorylation after surgery

Besides p38 MAPK, we also assessed another downstream regulator (RhoA/ROCK) of P2Y12 after spinal nerve injury. Western blotting was used to evaluate the expression of active-RhoA (GTP-RhoA, Fig. 6a) and ROCK2 (Fig. 6b) in the ipsilateral spinal cord after nerve injury. Their protein expression was time dependently increased at day 3, 7, and 14 after SNL surgery. We also evaluated the effect of Y27632 (ROCK inhibitor) on the expression of p-p38. Interestingly, Y27632 decreased the expression of p-p38 at day 7 after surgery (Fig. 6f–h), but the p38 inhibitor (SB203580) had no effect on the expression of ROCK2 (data not shown), which means that RhoA/ROCK2 signaling is upstream of p38 MAPK. However, the P2Y12 antagonist reversed the upregulation of ROCK2 after nerve injury (Fig. 6e–g), which means that P2Y12 is upstream of RhoA/ROCK2 signaling. Furthermore, Y27632 markedly attenuated the mechanical allodynia at days 1, 3, 5, and 7 (Fig. 6i) and thermal hyperalgesia at days 1, 3, and 5 after surgery (Fig. 6j) in the ipsilateral hind paw.

P2Y12 knockout mice exhibited fewer nociceptive behaviors and lower mEPSCs in the ipsilateral superficial dorsal horn after nerve injury

We used knockout mice to verify the effect of P2Y12 on neuronal properties. First, we confirmed...
that the mechanical and thermal withdrawal reflexes in the ipsilateral hind paw of P2Y12 knockout mice were also increased at days 1, 3, 5, and 7 after surgery compared with the sham mice (Fig. 7a–c). However, P2Y12 knockout mice showed fewer reflexes in response to the defined stimuli than the WT mice (Fig. 7a–c).

Previous studies have shown that P2Y12 is critical for chronic pain16,17,18, but how it affects pain is unclear. Thus, we wondered whether P2Y12 contributes to synaptic transmission and thereby influences neuropathic pain. As shown in our electrophysiological results, after SNL surgery, both mEPSCs frequency and amplitude in the spinal lamina II neurons were consistently increased in WT mice (frequency: WT Sham: 1.89 ± 0.16 Hz, WT PSNL: 7.17 ± 0.63 Hz, Fig. 7e–h; amplitude: WT Sham: 28.26 ± 0.27 pA, WT PSNL: 51.75 ± 0.30 pA, Fig. 7e–i; n = 10 in each group). As expected, besides the behavioral improvement compared to WT mice, P2Y12 knockout mice demonstrated less facilitation of mEPSCs after nerve injury. (Frequency: KO Sham: 1.80 ± 0.14 Hz, KO PSNL: 4.41 ± 0.46 Hz, Fig. 7e–h; amplitude: KO Sham: 28.30 ± 0.31 pA, KO PSNL: 37.82 ± 0.30 pA, Fig. 7e–i; n = 10 in each group). As the shape of EPSCs is determined by the amount of presynaptically released glutamate and the properties of postsynaptic glutamate receptors16, our results indicated that both presynaptic glutamate release and postsynaptic glutamate receptors may be enhanced in the spinal lamina II after SNL surgery, and this enhancement was reduced by P2Y12 knockout. As for resting membrane potential (RMP) and action potential (AP), postsurgery P2Y12 knockout mice did not show any significant differences compared to the postsurgery WT mice (RMP: WT Sham: −57.38 ± 1.53 mV, WT PSNL: −51.36 ± 0.82 mV, KO Sham: −56.88 ± 1.02 mV, KO PSNL: −52.24 ± 0.87 mV; AP: WT sham: 63.17 ± 4.70 mV, WT PSNL: 61.75 ± 2.92 mV, KO Sham: 62.62 ± 2.78 mV, KO PSNL: 63.05 ± 2.77 mV; n = 10 in each group (Fig. 7j–l)).

Discussion

In the present study, we found that P2Y12 antagonists attenuated SNL-induced nociceptive thermal hyperalgesia, which concurs with previous research on mechanical allodynia7. Consistent with previous studies18,19, P2Y12 expression in the dorsal horn was highly restricted to microglia (Fig. 3). As shown in Fig. 1a, the expression of P2Y12 was increased in the ipsilateral spinal cord after SNL surgery. The main reason for the P2Y12 upregulation in the ipsilateral spinal cord could be the increased expression of P2Y12 in individual microglia, but another possible reason could be microglia proliferation after nerve injury (Fig. S1).

Notably, we also employed another P2Y12 antagonist, clopidogrel20, which is a well-known, effective, orally administered antithrombotic compound targeting P2Y12 in platelets with safety profiles from an extensive clinical program21. It has been reported that the effect of clopidogrel on P2Y12 is dependent on its active metabolite generated during hepatic metabolism, and transfer across the blood–brain barrier has also observed22. We observed a significant effect of 10 mg/kg oral clopidogrel, which alleviated tactile allodynia and thermal hyperalgesia (Fig. 2f–h) in the ipsilateral hind paw after SNL. A previous study2 reported that a higher dose (25 mg/kg) achieved a rather longer-lasting effect on existing tactile allodynia.

In all events, whether microglia activation is influenced by P2Y12 should be determined. We confirmed that SNL surgery increased the expression of iba-1 in the ipsilateral spinal cord of rats. However, MRS2395 and clopidogrel partially reversed the upregulation of iba-1, indicating that P2Y12 antagonists can inhibit the activation of microglia in SNL rats (Fig. 4a, b). We also compared the fluorescence intensity of iba-1 between the ipsilateral and contralateral spinal cord in different treatment groups at 7 days after surgery. The fluorescence intensity of iba-1 and P2Y12 was significantly decreased after treatment with MRS2395 (Fig. 4c, d) in SNL rats. The morphology of microglia in the contralateral spinal cord of SNL rats indicated a non-activated state, with small cell bodies and more ramified
processes (Fig. 4c). However, the microglia in the ipsilateral side was significantly activated, exhibiting swollen cell bodies and retracted processes (Fig. 4c). However, after treatment with MRS2395, the activated state of microglia in the ipsilateral spinal cord diminished and they became nonactivated state with ramified processes (Fig. 4d). This
**Fig. 7** (See legend on next page.)
transformation indicates that the activation of microglia was obviously suppressed by MRS2395.

Peripheral nerve injury induces a dramatic activation of intracellular signaling cascades, such as MAPK signaling, many researches have been conducted on p38 MAPK. Consistent with these studies, our results verified that a robust increase of p38 MAPK phosphorylation occurred after SNL surgery (Fig. 5d, e). The behavioral experiments (Fig. 5h, i) showed that the inhibitor of p38 alleviated the pain behavior induced by SNL, which implies that activation of p38 in spinal microglia is a critical step in the pathogenesis of neuropathic pain. Additionally, the P2Y12 antagonist effectively inhibited the expression of p-p38 (Fig. 5f, g). Pharmacological inhibition of P2Y12 decreased the phosphorylation of p38 MAPK, but not vice versa, as p38 inhibition does not affect P2Y12 mRNA during neuropathic pain. This suggests that p38MAPK could be a downstream target of P2Y12 to modulate pain hypersensitivity.

RhoA, a member of a small molecular G-protein family, is involved in many cellular functions, including cytoskeletal rearrangement, cell motility, phagocytosis, and intracellular trafficking. RhoA cycles between inactive (GDP-bound) and active (GTP-bound) forms, its active form interacts with downstream effectors to regulate cellular functions. The best matched downstream effector of RhoA is Rho kinase (ROCK). Activation of the RhoA/ROCK pathway has been observed in various central nervous system disorders, such as stroke and inflammation in the brain. Importantly, RhoA/ROCK has been reported to play a key role in the activation of p38 MAPK in the spinal cord. It has been reported that RhoA/ROCK induces over-activation of the cytoskeleton, which may act as a scaffold for the trafficking of nociceptive signaling factors. Moreover, the inhibition of RhoA/ROCK leads to the alleviation of neuropathic pain in mice. Our results show that rats pretreated with a ROCK inhibitor exhibited less hyperalgesia after SNL (Fig. 6i, j). Therefore, the RhoA/ROCK pathway has a crucial role in neuropathic pain. Dynamic remodeling of the cytoskeleton, especially of actin filaments, which provides a network for trafficking intracellular proteins may be trafficked to improve our research.

Most important of all, we confirmed that nerve injury triggered changes in excitatory synaptic transmission in the ipsilateral spinal cord of mice. After nerve injury, there was an obvious increase in the frequency and amplitude of mEPSCs in layer II neurons in WT mice. However, in global genetic P2Y12 knockout mice, both presynaptic and postsynaptic changes were reduced (Fig. 7a–i), consistent with the decrease in pain behavior in P2Y12 knockout mice (Fig. 7a–c). These results indicate that P2Y12 was involved in the enhanced excitatory synaptic responses in SG neurons after nerve injury. Thus, P2Y12 in the lamina II is an attractive candidate protein related to neural plasticity. To our knowledge, no modulation effect of P2Y12 on synaptic transmission has been reported before.

In conclusion, our results suggest that P2Y12 is necessary for neuron–microglia interactions underlying neuropathic pain in the superficial dorsal horn lamina II (SG area) (Fig. 8). We provided evidence on P2Y12, which involved pain-related postsynaptic enhancement via microglia activation in the spinal lamina II after nerve injury. This study provides new insight into the effect of P2Y12 on pain circuitry.

Materials and methods

Animals

Adult male Sprague–Dawley rats weighing 250–300 g were obtained from Shanghai Laboratory Animal Center at the Chinese Academy of Science (Shanghai, China). Male C57BL/6 (WT) and P2Y12 knockout mice were gifts from Junling Liu’s lab (Department of Biochemistry and Molecular Cell Biology, School of Medicine, Shanghai Jiao Tong University, Shanghai, China). The rats were housed in groups of five in cages before surgery and individually after surgery. All the animals were housed on...
bedding in a room maintained at a constant temperature of 22–23 °C with an alternating 12/12 h light/dark cycle, and water and food were available ad libitum. Before every operation, six animals were randomly chosen for each group. The protocol was approved by the Animal Care and Use Committee of the Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University (SYXK [Shanghai, China] 2011-0128, January 1, 2011). All studies involving animals are reported in accordance with the ARRIVE (Animals in Research: Reporting in vivo Experiments) guidelines. All efforts were made to minimize the suffering and reduce the number of animals used. The overall experimental design involving rats is illustrated in Fig. 2a.

Spinal nerve ligation neuropathic pain model establishment in rats
To produce a spinal nerve ligation (SNL) model, the rats were anesthetized with isoflurane inhalation in 100% oxygen (induced at 5% and maintained at 2%) and placed in a prone position. A midline incision was made at the L4–S2 level. The left paraspinal muscles were separated from the spinous processes, and the L6 transverse process was removed to expose the L4 and L5 spinal nerves. The L5 spinal nerve was then isolated and tightly ligated with 4-0 silk thread. A sham surgery involved the same procedure without the ligation of the L5 spinal nerve.

Intrathecal cannulation
For repeated injection of drugs, i.t. cannulation was performed using a previously described method. Briefly, the rats were anesthetized with isoflurane inhalation in 100% oxygen (induced at 5% and maintained at 2%), and then a 6-cm PE-10 catheter (Becton Dickinson, Sparks, MD, USA) was inserted into the subarachnoid space at the L4–L5 level. During the surgery, the concentration of isoflurane was increased when necessary. Involuntary movements of the tail or hind limb were regarded as signs of dura penetration. The catheter was then advanced 1.5 cm into the subarachnoid space to reach the site of the lumbar enlargement. The external end of the catheter was sealed using heat. The correct location of the catheter was tested by i.t. injection of lidocaine (2%, 10 μl) on the next day, which reversibly paralyzed the bilateral hind limb for 10–15 min. Before drug administration, the rats were allowed to recover for 3 days. To avoid infection, penicillin was intraperitoneally (i.p.) administered during the surgery.

Drugs administration
Before delivering the drugs, the catheterized rats were briefly anesthetized with isoflurane and placed in a transparent Plexiglas box. They were then slowly injected with drugs (1 μl/min) via the exteriorized portion of the catheter with a micro-syringe (Hamilton, Reno, NV, USA) containing 10 μl of the drug followed by flushing with 10 μl normal saline (Baxter Healthcare, New York, NY, USA).

Different groups of rats (n = 6 per group) were treated with the P2Y12 antagonist MRS2395 (200 μg in 10 μl 5% DMSO, Sigma, St. Louis, MO, USA); the p38 MAPK inhibitor SB203580 (1 μg in 10 μl 10% DMSO, Sigma, St. Louis, MO, USA); the ROCK inhibitor Y27632 (3 μg in 10 μl normal saline, Sigma, St. Louis, MO, USA), or normal saline (10 μl) or 10% DMSO (10 μl) as controls. The oral drug administrated rats were gavaged with the orally active P2Y12 antagonist clopidoogrel (10 mg/kg, Abcam, Cambridge, MA, USA). The drugs were delivered three times per day for 6 days, from 1 day before SNL surgery to 5 days after surgery.

Tests of paw withdrawal threshold and latency
To evaluate the behavioral response to mechanical stimulation, the 50% paw withdrawal threshold was
determined using the up-down method as previously described. Briefly, the rats were placed in a transparent plastic cage with a wire mesh bottom. After 30 min of acclimatization, a series of von Frey filaments (0.4, 0.6, 1.0, 1.4, 2.0, 4.0, 6.0, 8.0, 10.0, and 15.0 g; Stoelting, Wood Dale, IL, USA) were sequentially applied to the plantar surface of the ipsilateral and contralateral paws. Brisk withdrawal and hind paw-licking were recognized as positive responses. If continuous positive or negative responses occurred until the exhaustion of the stimulus set, values of 0.4 and 15 g were assigned, respectively. Changes in general behavior including repetitive movements, vocalization or activity level were noted throughout testing.

Thermal hyperalgesia was measured using an IITC Plantar Analgesia Meter (IITC Life Science Inc., Woodland Hills, CA, USA) to measure paw withdrawal latency as described previously. Briefly, each animal was placed in a box containing a smooth, temperature-controlled glass floor. The heat source was focused on a portion of the hind paw, which was flush against the glass, and a radiant thermal stimulus was delivered to that site. The stimulus was shut off when the hind paw moved, or after 20 s to prevent tissue damage. The time from the onset of radiant heat to the endpoint was the paw withdrawal latency. The radiant heat intensity was adjusted to obtain a basal paw withdrawal latency of 10–12 s in control rodents. Thermal stimuli were delivered three times to each hind paw at 5–6 min intervals. All of the behavioral tests were assessed by an examiner who was blind to the treatment groups.

Western blotting

Rats were sacrificed at days 0, 3, 7, and 14 after surgery, and the spinal cord was collected for western blot analysis. Under deep anesthesia with pentobarbital (60 mg/kg, i.p.), rats were subjected to a rapid intra-cardiac infusion of ice-cold saline containing heparin. The lumbar enlargements were then harvested and immediately stored at −80 °C in a refrigerator. The dorsal portions of the lumbar enlargements (100 mg) were homogenized in 400 μl ice-cold RIPA lysis buffer (Beyotime, Shanghai, China) containing a cocktail of protease and phosphatase inhibitors. After incubation on ice for 15 min, the lysate was centrifuged at 12000×g and 4 °C for 20 min to isolate the proteins. The protein concentrations of the samples were determined with a BCA protein assay kit (Beyotime, Shanghai, China). Samples containing 50 μg protein were denatured by heating at 100 °C for 5 min, separated on sodium dodecyl sulfate-polyacrylamide gels, and transferred onto polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA). The membranes were blocked with 5% nonfat milk in Tris-buffered saline with Tween (TBST) for 2 h at room temperature. They were then incubated overnight at 4 °C with primary antibodies: rabbit anti-P2Y12 (1:1000, Anaspec Inc., MA, USA), rabbit anti-GAPDH (1:5000, Hangzhou HuaAn Biotechnology Co., Ltd., Hangzhou, China), mouse anti-iba-1 (1:500, Merck & Co Inc., NJ, USA), mouse anti-β-tubulin (1:5000, Hangzhou HuaAn Biotechnology Co., Ltd, Hangzhou, China), rabbit anti-pp38 (1:1000, CST, Danvers, MA, USA), rabbit anti-p38 (1:1000, Abcam, Cambridge, MA, USA), mouse anti-RhoA (1:500, Abcam, Cambridge, MA, USA), and rabbit anti-ROCK2 (1:500, Abcam, Cambridge, MA, USA). All primary antibodies were diluted in 5% nonfat milk in TBST. The membranes were then washed with TBST and incubated for 2 h at room temperature with corresponding horseradish peroxidase-conjugated secondary antibodies. Enhanced chemiluminescence reagent (Thermo Fisher Scientific, Rockford, IL, USA) was used to detect the signal, and ImageQuant Ai600 (General Electric Co., Kenilworth, NJ, USA) was used to visualize the image. The results were analyzed and quantified by ImageJ software (version 2.0, NIH, Bethesda, MA, USA). Each western blot analysis was performed at least six times, and consistent results were obtained.

RhoA activity assay

According to the manufacturer’s directions, active GTP-bound RhoA was detected in the lysates from spinal dorsal horn tissue in rats. The lysates were subjected to a pull-down assay using a RhoA activation assay kit (Abcam, Cambridge, MA, USA). Briefly, lysates were incubated for 1 h with anti-active-RhoA mouse monoclonal antibody and Protein A/G Agarose Bead slurry at 4 °C on a rotator. Bead-precipitated proteins were fractionated and then immunoblotted with antibody against RhoA.

Fluorescence immunohistochemistry

Regarding the fluorescence immunohistochemistry, rats were anesthetized and transectorily perfused with 4% cold paraformaldehyde on day 7 after surgery, lumbar spinal cords were harvested, postfixied for 2 h at 4 °C in 4% paraformaldehyde, and then dehydrated sequentially in 10%, 20 and 30% sucrose overnight for 3 days. The spinal sections were transversely cut into 30 μm slices in a cryostat and then washed in TBST. The sections were first blocked with 0.3% Triton X-100 in 5% donkey serum for 1 h at 20–25 °C. They were then incubated overnight at 4 °C with the following primary antibodies: goat anti-iba-1 (1:400, Abcam, Cambridge, MA, USA), mouse anti-GFAP (1:400, 1:1000, CST, Danvers, MA, USA), mouse anti-NeuN (1:400, Millipore, Billerica, MA, USA), mouse anti-olf-2 (1:200, Millipore, Billerica, MA, USA), rabbit anti-P2Y12 (1:1000, Anaspec Inc., MA, USA), rabbit anti-Ki67 (1:1000, Abcam, Cambridge, MA, USA), rabbit anti-pp38 (1:1000, CST, Danvers, MA,
immediately transferred to a jacketed water-nerv. The wounds were then closed, and the pups were group, the skin and muscle were just incised to expose the one-third of the sciatic nerve was ligated. In the sham the left sciatic nerve using 8-0 nylon such that one-half to

Pains from the orifices were tested. After every behavior test, points (0, 1, 3, 5, and 7 days) after the PSNL surgery, the pups were returned to their mothers. At several time

recovery from anesthesia, usually about 2 h after surgery, their mother to cover all surgery-related odors. Upon full

pad maintained at around 37 °C. Each pup was covered

1 g von Frey

odor changes from their mother.

where they lived with their mother for at least 1 h to hide each pup moved around in the padding from the cage nociceptive behavior was tested. After every behavior test, after deep anesthe-

tia, a tight ligature was placed around the dorsal half of thermic heating

of the ipsilateral hind paw (with the injured nerve

responses evident after surgery were de

Exes

strain and 2.5 s radiant thermal stimulus

labeled heating

was applied to the middle area between the footpads on

investigator for at least 1 h before the tests. Each stimulus

were acclimatized to the environment and

stimulation instead of lifting the paw, the test was rea-

valid only if the hind paw was removed completely from

Electrophysiology

The lamina II (SG area) in the superficial dorsal horn was visually identified as reported before

in spinal slices with a 60× water immersion objective attached to an upright microscope (ECLOPSE FN1, Nikon, Tokyo, Japan). mEPSCs were recorded from lamina II neurons using the whole-cell patch-clamp technique with an amplifier (EPC-10 usb, HEKA, Lambrecht, Germany), using the voltage-clamp mode with a pipette potential of

ACSF with 10 μM bicuculline and 1 μM strychnine to block GABAergic and glycinergic synaptic currents, and

100 nM tetrodotoxin (TTX) to block APs. When the electrode tip touched the cell membrane, gentle suction

was applied to form a tight seal (serial resistance > 2 GΩ).

Tests of frequency of withdrawal reflexes

Regarding the nociceptive behavior tests in mice, we counted the number of withdrawal reflexes in response to a sequential series of ten stimulations to the plantar surface of the ipsilateral hind paw (with the injured nerve

postmortem slicing of the spinal cord. R</parent_id>
At $-70 \text{ mV}$ command voltage, additional suction was applied to rupture the cell membranes. After obtaining recordings using the whole-cell mode, the recording was switched to current-clamping mode and the RMP was recorded. To compare the relative comprehensive excitability of the spinal lamina II neurons in different groups, we also examined the AP evoked by a 2 ms intracellular depolarizing current of 1000 pA. The electrode capacitance and liquid junction potential were compensated and data were filtered at 1–3 kHz and sampled at 3–10 kHz using a Dell computer equipped with Clampex software (Molecular Devices, Sunnyvale, CA, USA). The access resistance, which was monitored throughout the experiment, 15–30 MΩ. All electrophysiological recordings and data analyses were conducted by researchers blind to the treatment group.

Statistical analysis

GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA, USA) was used to conduct the statistical analyses. Changes in detected protein expression were tested using one-way repeated-measures analysis of variance (ANOVA), followed by the Dunnett’s multiple comparison test. Changes in behavior responses to von Frey filaments and radiant heat stimuli over time among the groups were tested using two-way repeated-measures ANOVA, followed by the Bonferroni post hoc test. The electrophysiology data were acquired by Clampfit 10.2 software (Molecular Devices, Sunnyvale, CA, USA) and analyzed using SPSS 22.0 software (IBM Corp, Armonk, NY, USA). The relative expression of target proteins in different groups was normalized to GAPDH, and the phosphorylation level of target proteins in different groups was normalized (IBM Corp, Armonk, NY, USA) and analyzed using SPSS 22.0 software. Changes in detected protein expression were tested using one-way repeated-measures analysis of variance (ANOVA), followed by the Dunnett’s multiple comparison test. Changes in behavior responses to von Frey filaments and radiant heat stimuli over time among the groups were tested using two-way repeated-measures ANOVA, followed by the Bonferroni post hoc test. The electrophysiology data were acquired by Clampfit 10.2 software (Molecular Devices, Sunnyvale, CA, USA) and analyzed using SPSS 22.0 software (IBM Corp, Armonk, NY, USA). The relative expression of target proteins in different groups was normalized to GAPDH, and the phosphorylation level of target proteins was compared with their total level. We set the mean value of the sham group to 1, and standardized every set of data accordingly. All data analyses were performed by researchers who were blind to the treatment groups. All data are presented as the mean ± SEM. Statistical differences were considered significant if $p < 0.05$.

Acknowledgments

We thank Dr. Junling Liu (Department of Biochemistry and Molecular Cell Biology, School of Medicine, Shanghai Jiao Tong University) for kindly providing us with P2Y12 knockout mice. This work was supported by grants from the National Natural Science Foundation of China (81672237 and 81370933, to D.P.D.; 81400803, to X.Z.).

Authors’ contributions

D.P.D. and X.Z. were responsible for subject direction and design. J.G.T. and T.T. Y. participated in establishing the animal model and behavioral test. T.T.Y. and L.L.S. performed the molecular biological experiments. H.S.S. performed the electrophysiology experiments and analyzed the relative data. T.T.Y., X.M.H., and W.Q.C. carried out the data analysis. D.P.D. and X.Z. obtained funding and provided administrative support. T.T.Y. and X.Z. were responsible for drafting the manuscript. D.P.D. supervised the whole study.

Author details

1Pain Management Center, Shanghai Jiao Tong University Affiliated Shanghai Sixth People’s Hospital, Shanghai 200233, China. 2Center for Translational Pain Medicine, Department of Anesthesiology, Duke University School of Medicine, Durham, NC, USA. 3Department of Otorhinolaryngology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, China. 4Department of Anesthesiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. 5Department of Integrative Medicine and Neurobiology, State Key Laboratory of Medical Neurobiology, School of Basic Medical Science, Institutes of Brain Science, Collaborative Innovation Center for Brain Science, Institute of Acupuncture and Moxibustion, Fudan Institutes of Integrative Medicine, Fudan University, Shanghai 200032, China.

Conflict of interest

The authors declare that they have no conflict of interest.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information accompanies this paper at (https://doi.org/10.1038/s41419-019-1425-4).

Received: 29 October 2018 Revised: 22 January 2019 Accepted: 1 February 2019

Published online: 18 February 2019

References

1. Tatsumi, E. et al. RhoA/ROCK pathway mediates p38 MAPK activation and morphological changes downstream of P2Y12/13 receptors in spinal microglia in neuropathic pain. Glia 63, 216–228 (2015).
2. Inoue, K. The function of microglia through purinergic receptors: neuropathic pain and cytokine release. Pharmacol. Ther. 109, 210–226 (2006).
3. Burnstock, G. Physiology and pathophysiology of purinergic neurotransmission. Physiol. Rev. 87, 659–797 (2007).
4. Sawynok, J., Downie, J. W., Reid, A. R., Cahill, C. M. & White, T. D. ATP release from dorsal spinal cord sympathetics: characterization and neuronal origin. Brain Res. 610, 32–38 (1993).
5. Tsuda, M. et al. P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature 424, 775–778 (2003).
6. Inoue, K. P2 receptors and chronic pain. Purinergic SignaL 3, 135–144 (2007).
7. Tozaki-Saitoh, H. et al. P2Y12 receptors in spinal microglia are required for neuropathic pain after peripheral nerve injury. J. Neurosci. 28, 4949–4956 (2008).
8. Liu, M. et al. P2Y12 receptor-mediated activation of spinal microglia and p38MAPK pathway contribute to cancer-induced bone pain. J. Pain Res. 10, 417–426 (2017).
9. Sipe, G. O. et al. Microglial P2Y12 is necessary for synaptic plasticity in mouse visual cortex. Nat. Commun. 7, 10905 (2016).
10. Honda, S. et al. Extracellular ATP or ADP induce chemotaxis of cultured microglia through G-coupled P2Y receptors. J. Neurosci. 21, 1975–1982 (2001).
11. Davalos, D. et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci. 8, 752–758 (2005).
12. Haynes, S. E. et al. The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat. Neurosci. 9, 1512–1519 (2006).
13. Pascual, O., Ben Achor, S., Rostang, P., Triller, A. & Bessis, A. Microglia activation triggers astrocyte-mediated modulation of excitatory neurotransmission. Proc. Natl Acad. Sci. USA 109, E197–E205 (2012).
14. Takiguchi, N. et al. Distinct degree of radiculopathy at different levels of peripheral nerve injury. Mol. Pain 8, 51 (2012).
15. Schneider, S. P. & Perl, E. R. Comparison of primary afferent and glutamate excitation of neurons in the mammalian spinal dorsal horn. J. Neurosci. 8, 2062–2073 (1988).
16. Maraggi, P. & Attwell, D. Role of glial amino acid transporters in synaptic transmission and brain energetics. Glia 47, 217–225 (2004).
17. Horvath, G. et al. Central P2Y12 receptor blockade alleviates inflammatory and neuropathic pain and cytokine production in rodents. Neurobiol. Dis. 70, 162–178 (2014).
18. Kobayashi, K. et al. P2Y12 receptor upregulation in activated microglia is a gateway of p38 signaling and neuropathic pain. J. Neurosci. 28, 2892–2902 (2008).
19. Kobayashi, K. et al. Neurons and glial cells differentially express P2Y receptor mRNAs in the rat dorsal root ganglion and spinal cord. J. Comp. Neurol. 498, 443–454 (2006).
20. Emmens, K. L. & Taylor, N. R. Contemporary issues in clopidogrel therapy: new evidence shaping clinical practice. Pharmacotherapy 27, 553–563 (2007).
21. Savi, P. & Herbert, J. M. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin. Thromb. Hemost. 31, 174–183 (2005).
22. Peeters, P. A. et al. Clopidogrel, a novel antiplatelet agent, and digoxin: absence of pharmacodynamic and pharmacokinetic interaction. Semin. Thromb. Hemost. 25(Suppl 2), 51–54 (1999).
23. Ji, R. R. & Stinchartz, G. Cell signaling and the genesis of neuropathic pain. Sci. STKE 252, re14 (2004).
24. Obata, K. & Noguchi, K. MAPK activation in nociceptive neurons and pain hypersensitivity. Life. Sci. 74, 2643–2653 (2004).
25. Kim, S. Y. et al. Activation of p38 MAP kinase in the rat dorsal root ganglia and spinal cord following peripheral inflammation and nerve injury. Neuroreport 13, 2485–2488 (2002).
26. Tsuda, M., Mizokoshi, A., Shigemoto-Mogami, Y., Koizumi, S. & Inoue, K. Activation of p38 mitogen-activated protein kinase in spinal hyperactive microglia contributes to pain hypersensitivity following peripheral nerve injury. Glia 45, 89–95 (2004).
27. Svensson, C. I. et al. Activation of p38 mitogen-activated protein kinase in spinal microglia is a critical link in inflammation-induced spinal pain processing. J. Neurochem. 86, 1534–1544 (2003).
28. Kobayashi, K., Yamanaka, H., Yamamoto, F., Okubo, M. & Noguchi, K. Multiple P2Y subtypes in spinal microglia are involved in neuropathic pain after peripheral nerve injury. Glia 60, 1529–1539 (2012).
29. Hall, A. L. B. A. A. Rho GTPases and their effector proteins. Biochem. J. 348, 241–255 (2000).
30. Shimokawa, H. & Rashid, M. Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol. Sci. 28, 296–302 (2007).
31. Kang, W., Shang, L., Wang, T., Liu, H. & Ge, S. Rho-kinase inhibitor Y-27632 downregulates LPS-induced IL-6 and IL-8 production via blocking p38 MAPK and NF-kappaB pathways in human gingival fibroblasts. J. Periodontal 89, 883–893 (2018).
32. Su, C. C. et al. Phenotypes of trypsin- and collagenase-prepared bovine corneal endothelial cells in the presence of a selective Rho kinase inhibitor, Y-27632. Mol. Vis. 21, 633–643 (2015).
33. Todd, A. J. Neuronal circuitry for pain processing in the dorsal horn. Nat. Rev. Neurosci. 11, 823–836 (2010).
34. Yoshimi, E., Yamamoto, H., Futuchi, Y., Shimizu, Y. & Takeshita, N. Sustained analgesic effect of the Rho kinase inhibitor AS1892802 in rat models of chronic pain. J. Pharmacol. Sci. 114, 119–122 (2010).
35. Mittal, N. et al. Select G-protein-coupled receptors modulate agonist-induced signaling via a ROCK, LIMK, and beta-arrestin 1 pathway. Cell Rep. 5, 1010–1021 (2013).
36. Kim, S. H. & Chung, J. M. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50, 355–363 (1992).
37. Storkson, R. V., Kjorsvik, A., Tjolosen, A. & Hole, K. Lumbar catherization of the spinal subarachnoid space in the rat. J. Neurosci. Methods 65, 167–172 (1998).
38. Chaplan, S. R., Bach, F. W., Pogrel, J. W., Chung, J. M. & Yaksh, T. L. Quantitative assessment of tactile allodynia in the rat paw. J. Neurosci. Methods 53, 55–68 (1994).
39. Hargreaves, K., Dubner, R., Brown, F., Flores, C. & Joris, J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32, 77–88 (1988).
40. Seltzer, Z., Dubner, R. & Shir, Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 43, 205–218 (1990).
41. Garraway, S. M. & Mendell, L. M. Spinal cord transection enhances afferent-evoked inhibition in lamina II neurons and abolishes BDNF-induced facilitation of their sensory input. J. Neurotrauma 24, 379–390 (2007).
42. Okamoto, M. et al. Functional reorganization of sensory pathways in the rat spinal dorsal horn following peripheral nerve injury. J. Physiol. 532, 241–250 (2001).